Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G versus SPORANOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G versus SPORANOX.
FULVICIN P/G vs SPORANOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubule-associated proteins, disrupting mitotic spindle formation and inhibiting fungal cell division.
Inhibits fungal cytochrome P450 (CYP450)-dependent lanosterol 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
250 mg orally twice daily for tinea infections; 500 mg orally twice daily for onychomycosis. Administer with a fatty meal to enhance absorption.
200 mg orally twice daily for 3-7 days; for onychomycosis: 200 mg orally once daily for 12 weeks.
None Documented
None Documented
Terminal elimination half-life: 9–24 hours (mean ~16 hours). Clinical context: prolonged half-life allows once-daily dosing; steady-state achieved within 2–3 days.
The terminal elimination half-life of itraconazole ranges from 21 to 35 hours for single doses, increasing to approximately 34 to 42 hours at steady state. The half-life of the active metabolite, hydroxyitraconazole, is similar. This long half-life allows for once-daily or twice-daily dosing in most indications.
Renal (largely unchanged, <1% as metabolites); biliary/fecal (minor). Approximately 36% of a dose is excreted in urine within 6 hours, and up to 50% within 72 hours.
Itraconazole is extensively metabolized in the liver via CYP3A4 to active metabolites, including hydroxyitraconazole. The parent drug and metabolites are primarily excreted in feces (approximately 54%) and urine (approximately 35%), with less than 1% of the dose excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal